Advertisement


Helena Margaret Earl, MBBS, PhD, on Early Breast Cancer: Results From the Persephone Trial

2018 ASCO Annual Meeting

Advertisement

Helena Margaret Earl, MBBS, PhD, of the University of Cambridge, discusses phase III study findings on 6 vs 12 months of adjuvant trastuzumab in patients with HER2-positive early breast cancer (Abstract 506).



Related Videos

Lymphoma

Jeremy S. Abramson, MD, on Non-Hodgkin Lymphoma: Results From the TRANSCEND NHL 001 Trial

Jeremy S. Abramson, MD, of the Massachusetts General Hospital, discusses study findings on lisocabtagene maraleucel in relapsed or refractory aggressive NHL (Abstract 7505).

Skin Cancer

Emily S. Ruiz, MD, MPH, on Squamous Cell Carcinoma: Expert Perspective

Emily S. Ruiz, MD, MPH, of Brigham and Women’s Cancer Center, discusses new developments in the treatment of squamous cell skin cancer and what she sees on the therapeutic horizon (Abstracts e18703, 9519, and 9577).

Survivorship
Integrative Oncology
Symptom Management

Jun J. Mao, MD, MSCE, on Insomnia in Cancer Survivors: Trial Results

Jun J. Mao, MD, MSCE, of Memorial Sloan Kettering Cancer Center, discusses study findings on the effect of acupuncture vs cognitive behavior therapy in cancer survivors experiencing insomnia (Abstract 10001).

Leukemia
Immunotherapy

Peter Hillmen, MB, ChB, on CLL: Results From the MURANO Trial

Peter Hillmen, MB, ChB, of St James’s University Hospital, discusses phase III study findings on minimal residual disease negativity with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia (Abstract 7508).

Prostate Cancer

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, on Prostate Cancer: Results of the SPCG-13 Trial

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, of Tampere University Hospital, discusses phase III findings on adjuvant docetaxel and surveillance after radical radiotherapy for intermediate- and high-risk prostate cancer (Abstract 5000).

Advertisement

Advertisement




Advertisement